Browsing category:

Anti-Diabetic

Sitagliptin Phosphate CAS No: 654671-78-0 Sitagliptin Phosphate was approved more than a decade ago primarily as a way to combat type 2 diabetes. This dipeptidyl-peptidase-4 inhibitor lowers the levels of glucose in the patient directly following a meal and can also help regulate general blood sugar levels over time. It’s usually used in combination with[…]

The Hyderabad-based pharmaceutical company, Lee Pharma, has recently released a statement which says that Saxagliptin hydrochloride is the most effective substitute for insulin injectables for the treatment of Type-2 diabetes. The statement was made while Lee Pharma said that the multinational company AstraZeneca, which it applied to for the patented diabetes medication Saxagliptin hydrochloride, was[…]

A new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals. According to reports, the cardiovascular[…]

Known as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients[…]

On January 16, 2015 the Journal of Diabetes and its Complications shared positive findings from a recent post hoc analysis of Canagliflozin. Comprehensive data was analyzed from Phase 3 studies of Canagliflozin in adult patients with type 2 diabetes. This placebo-controlled study was comprised of four 26 week periods, with changes in HbA1c being sought[…]

An article published in January 2015 in Diabetes, Obesity and Metabolism explored the pharmacodynamics and the benefits of Dapagliflozin and Canagliflozin in the fight against obesity and type 2 diabetes. This double-blind, randomized study involved both males and females between the ages of 18 and 55. All participants were deemed healthy and free of significant[…]

The close of 2014 brought exciting news for Novo Nordisk’s innovative weight loss drug Saxenda. The Liraglutide FDA approval is the first of its kind as it’s the only available injectable treatment for obesity. The FDA overwhelmingly gave a nod to this easy to use form of Liraglutide as a safe and effectual option for[…]

British-Swedish drugmaker AstraZeneca has been approved by the FDA for its once-a-day Xigduo XR extended-release tablet to treat adults with type 2 diabetes mellitus in the United States. AstraZeneca’s once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control. Xigduo XR is already approved in Australia, and Xigduo is[…]

The latest news in the fight against type 2 diabetes highlights Dapagliflozin and Saxagliptin as the latest dazzling duo. Known as the brand name medications Farxiga {Dapagliflozin} and Onglyza {Saxagliptin} these powerhouse drugs have proven themselves in Phase lll trials. Data recently released from the 534 patient, three-arm trial demonstrated that the combination treatment of[…]

Search Posts

Post Categories

Post Categories

Signup for our E-Newsletter

Email *

Yes, I would like to receive emails from LGM Pharma. (You can unsubscribe anytime)

Constant Contact Use.

By submitting this form, you are consenting to receive marketing emails from: LGM Pharma, 2758 Circleport Dr., Erlanger, KY, 41018, http://lgmpharma.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact